Spermidine Suppresses Peripheral Inflammation and Alleviates Non-Motor Symptoms in the 6-OHDA-Induced Rat Model of Parkinson's Disease.
In a 6-OHDA rat model, oral spermidine (short- and long-term) normalized peripheral immune markers (reversed lymphopenia, increased CD4+ T cells and monocytes, raised IL-4/IL-10, lowered corticosterone) and reduced anhedonia and anxiety-like non-motor symptoms without biochemical toxicity.
What the AI sees
In a 6-OHDA rat model, oral spermidine (short- and long-term) normalized peripheral immune markers (reversed lymphopenia, increased CD4+ T cells and monocytes, raised IL-4/IL-10, lowered corticosterone) and reduced anhedonia and anxiety-like non-motor symptoms without biochemical toxicity.
Research significance
This study provides translationally actionable evidence that spermidine supplementation can modulate peripheral immunity to alleviate PD-relevant non-motor symptoms, supporting repurposing and biomarker-guided clinical investigation.
Source abstract
Non-motor symptoms of PD impair quality of life and remain challenging to treat. Here, we examined the effects of short- (38 days) and long-term (178 days) supplementation with the natural polyamine spermidine on anhedonia and anxiety-like behaviours in a 6-hydroxydopamine-induced rat model of PD and linked them with spermidine's anti-inflammatory properties. Behavioural assessments (cylinder, sucrose preference, elevated plus-maze tests) were conducted during progressive neurodegeneration and after oral treatment. Under the same conditions, peripheral inflammation was evaluated by the total leukocytes and their subpopulation numbers (hematological analysis) and by CD4+ and CD8+ T lymphocyte percentages (imaging flow cytometry); the plasma levels of interleukins 4 and 10 and corticosterone (enzyme-linked immunosorbent assay) were also evaluated. The safety of long-term supplementation was assessed using standard biochemical markers (chemistry analyser). Both treatment regimens reversed 6-hydroxydopamine-induced lymphopenia. Long-term spermidine treatment increased the number of TCD4+ lymphocytes and monocytes and elevated the plasma concentrations of IL-4 and IL-10, while reducing corticosterone levels. These immunomodulatory effects were associated with reduced anhedonia and anxiety. All of the biochemical safety parameters remained within normal ranges. Spermidine alleviates neuropsychiatric symptoms in a rat model of progressive neurodegeneration in the nigrostriatal system through its regulatory influence on peripheral immune responses. Exploring the systemic mechanisms underlying spermidine's effects could unveil innovative supplementation strategies and expand treatment options for managing symptoms in PD.